trial

Alcoholism and Schizophrenia: Effects of Clozapine

NCTId NCT00169026
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Terminated
Enrollment 64
Sponsored by Dartmouth-Hitchcock Medical Center
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Terminated
Enrollment
64
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
1999-05
Primary completion
—
Eligibility
ALL · 19 Years · 65 Years

Interventions & indications

Drugs
Clozapine

Sponsors

Dartmouth-Hitchcock Medical CenterLead Sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)Collaborator
Harvard Medical School (HMS and HSDM)Collaborator
Commonwealth Research Center, MassachusettsCollaborator
Novartis PharmaceuticalsCollaborator

Investigators

1
Alan I. Green, MDPrincipal Investigator

Sites

1 total
Jamaica Plain, United States

Facts & assertions

3 sourced
Enrollment
64
Phase
PHASE4
Status
TERMINATED
relationships
The graph out of here
drug
Clozapine
drug
lead_sponsor
Dartmouth-Hitchcock Medical Center
company
collaborator
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
company
Harvard Medical School (HMS and HSDM)
company
indication
Psychotic Disorder
indication
Alcohol Abuse
indication
Schizoaffective Disorder
indication
investigator
Alan I. Green, MD
person